Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29873709 | 1.00 | PTGS2 (0.31) | PTGS2PTGS1 | |
| SCHEMBL21433858 | 0.92 | — | — | |
| SCHEMBL14645995 | 0.91 | PTGS2 (0.30) | PTGS2PTGS1 | |
| SCHEMBL20609994 | 0.89 | TDO2 (0.33) | — | |
| SCHEMBL29906286 | 0.89 | TDO2 (0.33) | — | |
| SCHEMBL29874052 | 0.89 | PTGS2 (0.32) | PTGS2PTGS1 | |
| SCHEMBL20165779 | 0.89 | PTGS2 (0.32) | PTGS2PTGS1 | |
| SCHEMBL15808721 | 0.88 | — | — | |
| SCHEMBL17180466 | 0.88 | — | — | |
| SCHEMBL15808924 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110177798-B | Catalyst and process for preparing same | 博里利斯股份公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11352376-B2 | Catalysts | BOREALIS AG (AT) | 2022-06-07 | — | — | US | disclosed |
| EP-3541823-B1 | CATALYSTS | BOREALIS AG (AT) | 2020-12-30 | — | — | EP | disclosed |
| US-20190308995-A1 | CATALYSTS | BOREALIS AG (AT) | 2019-10-10 | — | — | US | disclosed |
| EP-3541823-A1 | CATALYSTS | Borealis AG (AT) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091684-A1 | CATALYSTS | BOREALIS AG (AT) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352376-B2 | Catalysts | SIGMAR1, H1-2, SFN | PTGS2 3715/4885PTGS1 3898/4885 |
| US-20190308995-A1 | CATALYSTS | SIGMAR1, H1-2, CBR1 | PTGS2 3756/4885PTGS1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.